Clinical Research Services

The combination of the MHRA Accreditation and the expert knowledge of conducting 500 Early Phase Studies ensure Richmond Pharmacology can provide you with a service that meets your needs.

Adaptive Phase I Studies

Rapid approval, flexible conduct, adaptive protocols in a MHRA accredited facility.

View service

TQT Studies

World-class specialist clinic and core laboratory all under one roof.

View service

Bridiging Studies

International specialist provider of Japanese Bridging Studies since 2002.

View service

Patient Recruitment

Fast and efficient in-house team, specialising in patient recruitment

View service

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more